DLA Piper advises Kadmon Holdings in its acquisition by Sanofi

DLA Piper is representing Kadmon Holdings, Inc. (NASDAQ: KDMN) in its pending acquisition by global biopharmaceutical company Sanofi S.A. (NASDAQ: SNY) for approximately US$1.9 billion.

Kadmon is a biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Kadmon's pipeline includes product candidates for immune and fibrotic diseases, as well as immuno-oncology therapies.

“It was a pleasure to advise Kadmon in its merger with Sanofi, bringing together our first-rate public company M&A capabilities, a strong multidisciplinary team and our deep knowledge of the life sciences sector to facilitate a smooth transaction,” said Howard Schwartz, who led the DLA Piper deal team along with J.A. Glaccum.

In addition to Schwartz (Baltimore) and Glaccum (Houston), the DLA Piper team representing Kadmon included partners Rita Patel (Washington, DC), Cathryn Le Regulski (Northern Virginia), Paolo Morante (New York), Tom Geraghty (Chicago), Ron Brown (Wilmington) and Rebecca McKnight (Austin); and associates Melissa Sampson, Shirley Qin (both of Washington, DC), Erin Tripathi (Baltimore) and Annette Moreno (Mexico City).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 11 consecutive years, according to Mergermarket.

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.